Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting.

Biotechnology and Bioengineering
Haiguang YangPin Wang

Abstract

Development of methods to engineer gamma-retroviral vectors capable of transducing target cells in a cell-specific manner could impact the future of the clinical application of gene therapy as well as the understanding of the biology of transfer gene vectors. Two molecular events are critical for controlling the entry of gamma-retroviral vectors to target cells: binding to cell-surface receptors and the subsequent fusion of viral vector membrane and cellular membrane. In this report, we evaluated a method to incorporate a membrane-bound antibody and a fusogenic molecule to provide binding and fusion functions respectively, into gamma-retroviral vectors for targeted gene delivery. An anti-CD20 antibody and a fusogenic protein derived from Sindbis virus glycoprotein could be efficiently co-displayed on the surface of viral vectors. Vectors bearing anti-CD20 antibody conferred their binding specificity to cells expressing CD20. Enhanced in vitro transduction towards CD20-expressing cells was observed for gamma-retroviral vectors displaying both an antibody and a fusogen. We found that the biological activity of the fusogen played an important role on the efficiency of such a targeting strategy and were able to engineer several mut...Continue Reading

References

May 31, 1994·Annals of the New York Academy of Sciences·P D RobbinsS S Boggs
Nov 1, 1993·Virology·R A Lamb
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·S Snitkovsky, J A Young
Aug 18, 1999·Proceedings of the National Academy of Sciences of the United States of America·A L BoergerJ A Young
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·P L Zeitlin
Mar 20, 2001·Nature Reviews. Genetics·N Somia, I M Verma
Aug 3, 2001·Journal of Virology·K MorizonoI S Chen
Oct 18, 2001·Current Opinion in Biotechnology·D LavilletteF L Cosset
May 2, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lili YangLuk Van Parijs
Nov 6, 2002·The Journal of Cell Biology·David McDonaldThomas J Hope
Jun 14, 2003·Human Gene Therapy·Chien-Kuo TaiNoriyuki Kasahara
Mar 27, 2004·Nature Reviews. Microbiology·Dimiter S Dimitrov
Apr 19, 2005·Nature Biotechnology·Jianmin FangKarin Jooss
Jun 7, 2005·Expert Opinion on Biological Therapy·Andrea L Szymczak, Dario A A Vignali
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang HiddemannMichael Unterhalt
Jul 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Lili YangPin Wang
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Dec 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Martina BlumenthalDonald B Kohn
Jul 4, 2007·Nature Reviews. Genetics·Reinhard WaehlerDavid T Curiel
Nov 15, 2008·The Journal of the Association of Nurses in AIDS Care : JANAC·Tommie P Nelms, Vicki L Zeigler
Oct 1, 1996·TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·S P KhatiwadaP G Fernandez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

© 2022 Meta ULC. All rights reserved